KMT2A and intrahepatic cholangiocarcinoma: In the latest 2022 WHO and ICC classifications, cases with KMT2A and NUP98 rearrangements form independent AML subgroups, and cases with CBFA2T3::GLIS2 and RBM15::MKL1 belong to a subgroup of AML with other defined genetic alterations.